GLP-1 Showdown: Semaglutide vs Mounjaro—Which Is Better?

The rise of GLP-1 medications has transformed how doctors treat obesity and metabolic health. Among the most popular options are semaglutide (used in Ozempic and Wegovy) and tirzepatide, the active ingredient in Mounjaro. Both offer life-changing results—but how do they actually compare?

If you’re deciding between the two, here’s a detailed breakdown of how semaglutide and Mounjaro stack up in terms of effectiveness, side effects, cost, and patient experience.

Mechanism: GLP-1 vs GLP-1 + GIP

• Semaglutide works by mimicking GLP-1, a gut hormone that reduces hunger, slows digestion, and regulates insulin.
• Tirzepatide (Mounjaro) targets both GLP-1 and GIP receptors—meaning it can provide enhanced metabolic control and fat loss by acting on two pathways.

This dual-action is why many providers now consider Mounjaro to be more potent, especially for those with stubborn weight or insulin resistance.

Weight Loss Results: Which One Works Faster?

• Semaglutide (Ozempic/Wegovy): Clinical trials show average weight loss of 12–15% of body weight over several months.
• Mounjaro: Patients report losing up to 20–22% of body weight in the same timeframe—often with fewer food cravings.

Both require consistency, dose titration, and medical supervision. But based on current data, Mounjaro tends to outperform semaglutide, especially in early fat loss phases.

Side Effects: What Patients Report

Shared side effects:

• Nausea
• Constipation
• Fatigue
• Diarrhea or burping
• Appetite suppression (desired)

Differences:

• Semaglutide users often experience nausea early but adjust quickly.
• Mounjaro users report slightly stronger GI symptoms during dose changes—but also stronger appetite control.

Most side effects fade over time, especially with slow dose titration and guidance from a licensed provider.

Cost Comparison in 2025

Both drugs are expensive without insurance:

• Semaglutide (Ozempic/Wegovy): $1,300–$1,500/month retail
• Mounjaro (Tirzepatide): $1,200–$1,400/month retail

Fortunately, compounded options through telehealth providers like Meya make both treatments affordable:

• Compounded semaglutide or tirzepatide
• Flat pricing at $196/month
• Includes medical intake, provider review, and delivery
• No insurance required

This makes both medications accessible to anyone who qualifies medically.

Which Should You Choose?

Choose Semaglutide if you:

• Prefer a more established option (used since 2017)
• Want slightly milder side effects
• Are starting GLP-1 for the first time

Choose Mounjaro if you:

• Have a higher starting weight or insulin resistance
• Want faster results
• Don’t mind slightly stronger side effects for more dramatic outcomes

Both are safe, powerful, and effective—with the right supervision.

Conclusion: Two Great Tools, One Affordable Path

Whether you go with semaglutide or Mounjaro, you’re choosing a clinically proven treatment that can dramatically improve weight, blood sugar, and overall health. And thanks to telehealth access, cost no longer has to be a barrier.

Want real GLP-1 treatment without the $1,300/month price tag? Start your journey with Meya for just $196/month.